ISI analyst Vijay Kumar reported Qiagen N. V. QGEN may have repercussions from reimbursements from coding changes issues.
Qiagen short interest rose to a 2-Year high before the third quarter. Kumar noted that Quest Diagnostics Inc. DGX preliminary earnings are taking a hit due to increased diagnostic coverage denial, missing 3Q estimates. This hit may hurt Qiagen despite the fact that shares are currently up 0.19% today. QGEN is underperforming the broader averages missing the percent and a half with the rest of the market.
Qiagen closed at $20.80 on Wednesday. Quest closed at $61.70 and is currently trading at -4.72%.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in